INVENTIONS FOR LICENSE
MCL 3345.0: Rab3B for the Treatment and Prevention of Parkinson's Disease
Ole Isacson, M.D. Ph.D., et al.
- Novel Target for Parkinson's Disease
Background and DescriptionParkinson's Disease (PD) is a chronic, progressive motor system disorder affecting as many as one million Americans, that can arise from environmental and/or genetic factors. Regardless of specific etiology, it has been found that dopaminergic neurons in the A9 region of the brain (substantia nigra pars compacta) are considerably more vulnerable than dopaminergic neurons in the immediately adjacent A10 region (ventral tegmental area). It is likely that different gene products expressed in the A10 neurons provide a neuroprotective effect. Based on extensive gene expression studies comparing A9 and A10 neurons, the inventors have discovered that elevated levels of the protein Rab3B are neuroprotective of dopaminergic neurons. Rab3B overexpression in A9 neurons of rodents caused an increase in the striatal dopamine content and in the expression levels of certain Rab3 effector proteins, resulting in significant neuroprotection of the A9 neurons.
Potential Commercial UsesThis invention features methods for the treatment or prevention of PD by increasing the expression or activity of Rab3B (e.g. introducing Rab3B protein or nucleic acid into the A9 region of the brain). By identifying a novel target for PD, this invention will lead to safer, more specific, and more powerful treatments for PD, which would be of great importance given the prevalence of this disease in our aging populations. Current therapy for PD, such as the use of the dopamine precursor L-DOPA to replace brain dopamine, has had only limited effectiveness.
Publication and Patent Status
A U.S. patent application claiming this invention has been filed. The research underlying the invention has been published as Chung et al. PNAS 106(52):22474-9 (2009).
McLean Hospital is offering a worldwide exclusive license to this technology.
For more information, please contact:Anne Ritter, Licensing Manager
Partners Research Ventures and Licensing